Opinion on Therapy Area in South and Central America

Published within

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

Type Product title / description Pub Price
ResearchWire
ResearchWire

Insomnia: serotonin agonists set to expand market

Published By Datamonitor
01 May 2007
Expert View
Expert View

Inhaler devices are still a major hurdle in asthma and COPD treatment

Inhaled drug delivery has major advantages over other methods of administration but inhalers can be difficult to use, and those devices which overcome the problems of the majority of inhalers often lack broad availability across molecules and drug classes. A range of therapies in the same type of device would improve proper use of inhalers, which could have a positive impact on treatment.

Published By Datamonitor
04 Jun 2008
ResearchWire
ResearchWire

Influenza vaccines: pandemic threat to fuel market growth

Published By Datamonitor
08 Jun 2006
ResearchWire
ResearchWire

Inflammatory bowel disease: next-generation TNF's threat to Remicade

Published By Datamonitor
01 Dec 2006
Expert View
Expert View

Inflammatory bowel disease: new treatments won't set market alight

Inflammatory bowel disease (IBD), primarily constituted of ulcerative colitis and Crohn's disease, affects approximately 1.8 million people in the seven major markets. Datamonitor forecasts a growing market and the launch of six major brands in IBD indications in as many years. However, few appear to offer especially novel mechanisms of action.

Published By Datamonitor
28 Feb 2007
CommentWire
CommentWire

Indevus Pharmaceuticals: Valstar reintroduced into bladder cancer market

Having previously been withdrawn due to purity concerns, Indevus Pharmaceuticals' Valstar has received FDA approval for reintroduction into the bladder cancer market. The drug should be able to reclaim its original market share, although this will require an effective marketing strategy. Indevus must ensure that Valstar can withstand potential competitive pressure in the future.

Published By Datamonitor
02 Mar 2009
Expert View
Expert View

Immunization against S. aureus has potential in selected target groups

Staphylococcus aureus bacteria have become a key concern in both the hospital and community setting. The spread of resistant strains, such as MRSA, underlines the urgent need for new strategies to treat and prevent these infections. Prophylactic vaccination of target groups could be a useful tool, but prudent group selection combined with alternative prevention strategies, will be key to success.

Published By Datamonitor
17 Jul 2008
CommentWire
CommentWire

ICAD 2009: tau emerges as a viable target for immunotherapy in Alzheimer's

Despite being one of the two hallmarks for Alzheimer's disease for over a century, little drug development has focused on tau as a therapeutic target. At this year's International Conference for Alzheimer's Disease, two groups presented data suggesting the viability of tau as a target for vaccine development, offering an alternative target for companies keen to boost their neurology pipelines.

Published By Datamonitor
22 Jul 2009
Expert View
Expert View

ICAD 2009: search for Dimebon's mode of action focuses on mitochondria

In July, Datamonitor attended the International Conference on Alzheimer's Disease in Vienna. At the meeting, Pfizer/Medivation presented some interesting preclinical data and results from a trial investigating the use of Dimebon in combination with market leader Aricept. These presentations shed more light on the drug's mode of action, and indicate Pfizer's positioning strategy for the drug.

Published By Datamonitor
22 Jul 2009
Expert View
Expert View

ICAD 2009: beta-amyloid remains center stage at Alzheimer's disease conference

In recent years, the annual International Conference on Alzheimer's Disease has become the foremost event on the Alzheimer's disease calendar. As a primary hallmark of the disease, beta-amyloid production and deposition have become the focus for drug development. At this year's meeting progress was reported on several beta-amyloid targeted clinical stage pipeline drugs.

Published By Datamonitor
22 Jul 2009

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

No help is available.